Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Goodwill & Intangibles (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Goodwill & Intangibles data on record, last reported at $3.4 million in Q1 2025.

  • For Q1 2025, Goodwill & Intangibles fell 99.37% year-over-year to $3.4 million; the TTM value through Mar 2025 reached $3.4 million, down 99.37%, while the annual FY2024 figure was $195.0 million, 64.36% down from the prior year.
  • Goodwill & Intangibles reached $3.4 million in Q1 2025 per MRVI's latest filing, down from $195.0 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $547.0 million in Q4 2023 and bottomed at $3.4 million in Q1 2025.
  • Average Goodwill & Intangibles over 5 years is $294.1 million, with a median of $235.4 million recorded in 2022.
  • Peak YoY movement for Goodwill & Intangibles: soared 5852.28% in 2021, then plummeted 99.37% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $270.4 million in 2021, then decreased by 19.86% to $216.7 million in 2022, then soared by 152.47% to $547.0 million in 2023, then tumbled by 64.36% to $195.0 million in 2024, then tumbled by 98.26% to $3.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Goodwill & Intangibles were $3.4 million in Q1 2025, $195.0 million in Q4 2024, and $201.9 million in Q3 2024.